CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25934886.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2554.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this phase I pharmacokinetic study of ABI-007, which was published in the May 1, 2002, issue of Clinical Cancer Research, Ibrahim and colleagues provided the framework needed for subsequent studies to confirm the benefits of ABI-007 over solvent-based formulations. Since the study's publication, experiments have highlighted the importance of drug-delivery systems, the immune system in cancer biology, and immunoregulatory properties of taxane compounds.
Medical subject headings
- Albumin-Bound Paclitaxel
- Antineoplastic Agents
- Nanoparticles
- Neoplasms